Login to Your Account



Tasimelteon Tames Circadian Rhythms in Phase III Testing

By Catherine Shaffer
Staff Writer

Wednesday, December 19, 2012
Advocates for the blind community are hailing new Phase III results for a drug that could provide relief from the debilitating symptoms of non-24-hour syndrome, a disorder in which the body is unable to reset its body clock to a 24-hour day, and which affects a majority of blind people because of the lack of light perception.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription